Sermorelin vs. tesamorelin: which evidence belongs to which drug?

Start with the condition, not a stronger-peptide ranking

Sermorelin and tesamorelin are different medicines, and a shared connection to growth-hormone release does not make their evidence interchangeable. The useful comparison starts with the proposed goal and the actual product. “Which is stronger?” skips the questions of what was studied, in which population and for which outcome.

I would be skeptical of a comparison that gives one universal winner for belly fat, sleep, strength and cognition. Those are separate claims. A drug can have evidence for one use without establishing another, and a product’s approved indication cannot be transferred to a different compounded preparation or ingredient.

Tesamorelin has a specific approved use

The EGRIFTA WR label indicates tesamorelin for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for weight-loss management, and long-term cardiovascular safety has not been established. ^[1]

That distinction matters when “belly fat” is used as a broad shopping term. A trial or label about a defined clinical population does not automatically answer a general weight-loss question. Ask the clinician to explain why the research population is relevant to your own circumstances and whether the proposed use matches the labeled one.

The phrase “FDA-approved peptide” is also incomplete without a product and indication. If the proposed prescription is compounded, ask about the finished product rather than assuming a brand label applies unchanged. A comparison page should keep the approved product, a compounded product and the ingredient’s research history visible as different subjects.

Sermorelin’s Geref history answers a different question

FDA’s 2013 determination concerned specific Geref injection products and found they had not been withdrawn for reasons of safety or effectiveness. The notice distinguishes pediatric treatment from diagnostic products. It does not establish a current adult wellness indication for every sermorelin formulation. ^[2]

The two histories therefore cannot be put into a simple “approved versus unapproved ingredient” contest. They concern particular finished products and uses. Our Geref and compounding guide provides the historical context; the practical next step is to identify exactly what a provider would prescribe today.

Write down the full name, formulation, route and dispensing pharmacy. If the clinician changes the proposal after reviewing your history, update the comparison rather than continuing to evaluate the original marketing description. That small habit prevents a category-level explanation from replacing a product-specific one.

The cognition paper is another common mix-up

A 2012 controlled trial enrolled 152 adults aged 55–87, including people with mild cognitive impairment, and studied tesamorelin for twenty weeks. It reported a favorable overall cognitive effect, with an executive-function signal; it did not establish prevention of dementia. ^[3]

A reference to “GHRH and cognition” can obscure the intervention. If a sermorelin page cites this trial, the relevance is indirect unless the author explains why and how it informs the different prescription. Calling both interventions GHRH-related does not erase the distinction.

Our trial explanation keeps the exact drug visible. It also separates performance on selected tests from the much larger question of preserving everyday independence. For readers worried about memory, that gap matters more than deciding which molecule sounds newer or more potent.

What happened when tesamorelin was stopped?

A follow-up trial in people with HIV and abdominal fat accumulation found that visceral-fat reduction was sustained during continued tesamorelin treatment, while fat reaccumulated after discontinuation. The result describes that population and outcome; it does not establish what happens after stopping sermorelin. ^[4]

I see this as a useful reason to ask about duration and reassessment before purchasing a long plan. Does the proposed benefit require continuing treatment? What evidence supports that expectation? What will be evaluated when the plan is reviewed? These are fair questions even when the available research cannot provide a precise individual forecast.

Do not turn a withdrawal finding from one medicine into a reason to continue another indefinitely. The evidence should guide the question, while the prescribing clinician handles the personal decision. The follow-up study reading describes how the comparison was conducted.

Keep three evidence lanes separate

The table is a way to organize the sources discussed above, not a clinical ranking. It is deliberately less tidy than an overall score because the underlying questions are less tidy. A provider comparison can assess service transparency while leaving treatment suitability to a clinician.

Compare the care arrangement after clarifying the medicine

Once you understand the proposal, compare consultation access, pharmacy information, follow-up and the total financial commitment. The Sermorelin Wise provider notebook is organized around published service details, not claims that one peptide is universally better. Use the quote comparison to record the actual offer rather than a headline price.

For the appointment, bring this single question: “Which evidence directly supports this product for the goal we are discussing?” A clear answer may include both relevant findings and remaining uncertainty. Put the response into your consultation brief. That is more useful than leaving with a stronger-sounding name and no explanation of what it is supposed to improve.